Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hexima Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and is being processed within a distinct art unit. WAYNESHAOBIN ZHONG is the busiest examiner for the portfolio, as he is responsible for the pending office action currently active.
The presence of only a single pending office action indicates a very focused prosecution stage for the company. With the distinct examiner and the distinct art unit involved, the company's interactions with the USPTO are consolidated. This lack of diversity in examiners or art units means that the strategy for the pending office action can be specifically tailored to the preferences of the busiest examiner and the rules of the single art unit.
In the Biotechnology & Pharmaceuticals area, where prosecution can be complex, having only the pending office action simplifies the management of the portfolio. The fact that WAYNESHAOBIN ZHONG is the busiest examiner with the 1 pending office action confirms that there are no other examiners currently reviewing pending matters for the company. This singular focus allows for a dedicated approach to the distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHONG, WAYNESHAOBIN | 1 | 72.3% | +21.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18898088 | INSECTICIDAL PROTEINS FROM PLANTS AND METHODS FOR THEIR USE | ZHONG, WAYNESHAOBIN | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18898088 | INSECTICIDAL PROTEINS FROM PLANTS AND METHODS FOR THEIR USE | ZHONG, WAYNESHAOBIN | 1662 | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHexima Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Wayneshaobin Zhong has the most, with 1 of Hexima Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
